1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Eli Lilly Inks Another Radiopharma Deal, Gaining Option to Buy Startup

17 Jul 2024
Admin
News Article

Eli Lilly Inks Another Radiopharma Deal, Gaining Option to Buy Startup

Overview

Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1 billion.

Lilly will pay Radionetics $140 million upfront for the option rights under the deal, which the companies announced Monday. Radionetics will continue to build its radiopharmaceutical drug pipeline through an “exercise period,” after which Lilly can choose whether to acquire the company.

Small Molecule Radiopharmaceuticals

Radionetics is developing small molecule radiopharmaceuticals that can target G protein-coupled receptors, a ubiquitous family of proteins that present many attractive disease targets.
The company’s focus is on solid tumors.Radiopharmaceuticals, a targeted alternative to radiation therapy, have become an area of significant pharmaceutical investment.
Large firms like Lilly, Bristol Myers and AstraZeneca have made acquisitions to get into the space, lured by technical improvements, clinical successes and regulatory approvals.

Drug History

Historically, the drugs have been challenging to manufacture and deliver, requiring tightly managed supply chains to ensure the radioisotopes they contain don’t decay. The surge in investment has helped to drive a biotech build-out in capacity.

Lilly has already been active in the field this year, paying startup Aktis Oncology $60 million in May for rights to develop treatments discovered by the company against targets selected by Lilly.

Largest Investment

Its largest investment came last year, though, when it bought out Point Biopharma for $1.4 billion.
The deal gave the company three clinical-stage candidates, including two that could compete with radiopharmaceuticals from Novartis.
Those therapies, Pluvicto and Lutathera, made the company over $1.5 billion in sales last year.

For Developing Nonpeptide Radiopharmaceuticals

Radionetics spun out from Crinetics Pharmaceuticals in 2021 with $30 million to develop nonpeptide radiopharmaceuticals for a “broad range of oncology indications.” The company then raised a Series A of $52.5 million early this year.
The startup is backed by investors such as 5AM Ventures, Frazier Life Sciences, DCVC Bio, GordonMD Global Investments and by Crinetics Pharmaceuticals.